Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant 2014 Oct;20(10):1485-92
Date
05/28/2014Pubmed ID
24862638Pubmed Central ID
PMC4163123DOI
10.1016/j.bbmt.2014.05.015Scopus ID
2-s2.0-84912522258 (requires institutional sign-in at Scopus site) 40 CitationsAbstract
Two parallel phase II trials in adults with hematologic malignancies demonstrated comparable survival after reduced-intensity conditioning and transplantation of either 2 HLA-mismatched umbilical cord blood (UCB) units or bone marrow from HLA-haploidentical relatives. Donor choice is often subject to physician practice and institutional preference. Despite clear preliminary evidence of equipoise between HLA-haploidentical related donor and double unrelated donor UCB transplantation, the actual prospect of being randomized between these 2 very different donor sources is daunting to patients and their treating physicians alike. Under these circumstances, it is challenging to conduct a phase III randomized trial in which patients are assigned to the UCB or haploidentical bone marrow arms. Therefore, we aimed to provide an evidence-based review and recommendations for selecting donors for adults without an HLA-matched sibling or an HLA-matched adult unrelated donor.
Author List
Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, Fuchs EJAuthor
Mary Eapen MBBS, DCh, MRCPI, MS Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Bone Marrow TransplantationCord Blood Stem Cell Transplantation
Decision Trees
Gene Expression
HLA Antigens
Haplotypes
Hematologic Neoplasms
Histocompatibility Testing
Humans
Myeloablative Agonists
Randomized Controlled Trials as Topic
Recurrence
Siblings
Survival Analysis
Transplantation Conditioning
Transplantation, Homologous
Unrelated Donors
